Tumor News and Research

RSS

Genetics of imatinib resistance in acute lymphoblastic leukemia

In the September 15th issue of Genes & Development, Drs. Richard T. Williams, Willem den Besten, and Charles J. Sherr at Howard Hughes Medical Institute, St. Jude Children's Research Hospital in Memphis TN, lend new insights into how an aggressive form of acute lymphoblastic leukemia (ALL) develops, and how sensitivity to the targeted chemotherapeutic drug, imatinib, can be diminished through interactions between tumor cells and the host microenvironment.

30 Aug 2007

Researchers discover what makes lymphomas tick

University of Pennsylvania researchers and their colleagues at the Wistar Institute and University of Oxford have discovered the molecular process by which the PAX5 protein, necessary for lymphocyte development, promotes the growth of common lymphomas, thereby unveiling a potential new target in the fight against cancer.

30 Aug 2007

Biologic treatment for rheumatoid arthritis and the risk of cancer

The relationship between rheumatoid arthritis (RA), an autoimmune disease marked by chronic inflammation of the joints and tissue surrounding vital organs, and the incidence of cancer is complicated.

30 Aug 2007

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007

St. Jude discovers factors that accelerate resistance to Gleevec targeted therapy in lymphoblastic leukemia

Results of a study by investigators at St. Jude Children's Research Hospital provide strong evidence for why the drug imatinib (Gleevec), which has revolutionized the treatment of chronic myelogenous leukemia (CML), is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL).

29 Aug 2007

Hypnosis session before breast cancer surgery aids recovery

Researchers say women who undergo surgery for breast cancer may be helped in the recovery process if they have a hypnosis session beforehand.

29 Aug 2007

IDM Pharma receives not approvable letter for Mifamurtide for treatment of osteosarcoma

IDM Pharma, Inc. ( NASDAQ:IDMI ) announced today that it received a not approvable letter from the U.S. Food and Drug Administration (FDA) after completing the review of the new drug application (NDA) for the investigational drug mifamurtide (L-MTP-PE), formerly known as Junovan, for the treatment of non-metastatic osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.

28 Aug 2007

Geron demonstrates hESC-derived cardiomyocytes improve heart function after myocardial infarction

Geron Corporation has reported its scientists and collaborators have demonstrated that human embryonic stem cell (hESC)-derived cardiomyocytes improve heart function when transplanted after myocardial infarction.

28 Aug 2007

Breast epithelial cells serve as a barrier against cancer

Sheets of highly organized epithelial cells line all the cavities and free surfaces of the body, forming barriers that control the movement of liquids and cells in the body organs.

28 Aug 2007

Scientists reveal the actions of a key player in colorectal cancer

Colorectal cancer is one of the most prevalent cancers in the Western world. The tumor starts off as a polyp but then turns into an invasive and violent cancer, which often spreads to the liver.

28 Aug 2007

Blocking angiogenesis signaling from inside cell may lead to serious health problems

Angiogenesis inhibitors that block a tumor's development of an independent blood supply have been touted as effective cancer fighters that result in fewer side effects than traditional chemotherapy.

24 Aug 2007

Nanoparticle drug delivery system for brain tumor therapy shows promise

A nanoparticle drug delivery system designed for brain tumor therapy has shown promising tumor cell selectivity in a novel cell culture model devised by University of Nottingham scientists.

24 Aug 2007

Potential new leukemia drug

In a new study, Danilo Perrotti and colleagues from Ohio State University, Columbus, show that treatment with a drug known as FTY720 prevents disease in a mouse model of many leukemias caused by the cancer protein BCR-ABL (nearly all cases of blast crisis chronic myeloid leukemia [CML-BC] and some cases of acute lymphocytic leukemia [ALL]).

24 Aug 2007

In the junk lies treasure when it comes to DNA

Three micro RNA genes appear to be key partners of protective gene p53; their loss is linked to common type of lung cancer

24 Aug 2007

Study looks at large burns

Large burns can trigger cardiac problems and enhanced inflammatory and hypermetabolic responses in patients, a study in the online open access journal Critical Care suggests.

24 Aug 2007

Rapamycin study is first stage in development of new treatment

Rapamycin isn't your ordinary potential anti-cancer drug…It had a long and somewhat exotic history before undergoing preclinical (laboratory-based) studies at St. Jude as part of a national Pediatric Preclinical Testing Program (PPTP) investigation of its anticancer activity.

23 Aug 2007

Cancer stem cell scientists get $1.7 million to develop new leukemia drugs

"Modern cancer treatments fail to get to the root of the cancer - the stem cells - which is why many cancers recur despite aggressive treatment."

23 Aug 2007

Cell-based sensor for analysis of EGFR biomarker expression in oral cancer

Using a microfluidic device designed to capture and enrich cells from biological samples, a research team at The University of Texas at Austin has developed a test that can detect an important early marker for oral squamous cell carcinoma, which accounts for more than 90 percent of oral cancers. Oral cancer is the sixth most common cancer worldwide and is difficult to detect early enough to treat successfully.

22 Aug 2007

Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy

Using metal nanoshells designed to both absorb and scatter near-infrared light, a team of investigators at Rice University has shown that such nanoparticles can both image and treat tumors in animals. Their experiments revealed complete tumor destruction in more than 80 percent of animals treated with these nanoshells.

22 Aug 2007

Nanotubes offer new approach to cancer radiotherapy

Radioactive elements, or radionuclides, are well-established anticancer agents whose main limitation is that they kill healthy cells almost as easily as they do tumors. But because nanoparticles can be targeted to tumors, researchers have seized on the idea of using nanoparticles to deliver radionuclides to tumors, thus sparing healthy tissues from radiation-induced damage.

22 Aug 2007